Docetaxel

Mechanism :

Chemotherapy agent that Inhibits DNA, RNA, and protein synthesis by inhibiting depolymerization of microtubules.

Indication :

• Refractory solid tumor, ongoing Phase I clinical trials.

Contraindications :

• Hypersensitivity reaction.

• Solid tumor with an absolute neutrophil count less than 1500/mm3

Women should avoid pregnancy at least 6 months after the last dose because of the risk of teratogenic potential.

Due to the potential risk to the child, the drug should be discontinued for at least 1 week, and then can start breastfeeding.

Dosing :

Adverse Effect :

Hair loss, Pancytopenia, Asthenia, increased risk of infections, fever, hypersensitivity, nausea, vomiting, sensory neuropathy, fluid retention, hepatotoxicity, and diarrhea.

Interaction :

• Apalutamide, enzalutamide: decreases the effect by affecting CYP3A4 metabolism.

• Chloramphenicol, fexinidazolel, idelalisib, itraconazole, lonafarnib, nefazodone, tucatinib, voxelotor: increases level by metabolism.

• Deferiprone, influenza virus vaccine quadrivalent, adjuvanted, influenza virus vaccine trivalent, adjuvanted: antagonistic action

• Erdafitinib, lasmiditan, palifermin, quinidine, ropeginterferon alfa 2b, selinexor, tepotinib: Increase the level of docetaxel.

• Sotorasib: decrease the level.

Hepatic Dose :

Avoid use if high bilirubin, AST/ALT is 1.5x normal, and AP 2.5x normal.

Dose reduction if isolated AST/ALT is 1.5x.